TayCom Biotech's Dual Engine Drives First 7-Month Revenue to NT$833 Million, Second-Highest Ever, Shares Surge Over Half-Stop Limit

TayCom Biotech (6589-TW) has reported revenue of NT$833 million for the first seven months of the year, the second-highest in its history, driven by steady growth in its CDMO business and the recognition of milestone payments from two HER2 biosimilars, EG12014 and EG1206A. This strong performance has led to a share price surge of over half the daily limit today (10th), reclaiming the 50-day moving average and the half-year line.

The stock opened at NT$50.2 this morning, jumping higher at the open, and rose as high as NT$52.6 during trading, approaching the daily upper limit. As of 10:00 a.m., the share price stood at NT$51.3, up over half the daily limit. It has reclaimed the NT$50 psychological barrier and the half-year moving average, with trading volume reaching approximately 1,000 shares.

TayCom's revenue for July alone reached NT$212 million, up 86.93% month-on-month and 184% year-on-year, marking a three-year high. Cumulative revenue for the first seven months totaled NT$833 million, a 70.91% year-on-year increase, the second-highest in company history.

Chairman Liu Li-Cheng stated that EG1206A has entered the final preparation stages for market approval, with plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) by the end of this year, while simultaneously filing a Biologics License Application (BLA) with the U.S. FDA. Partner companies have already begun planning for global market submissions.

As EG1206A progresses through development, the majority of product licensing-related milestone payments are expected to be realized between 2027 and 2028, serving as a key revenue driver over the next two years.

Regarding the CDMO business, Chairman Liu emphasized TayCom’s ability to offer end-to-end services for biosimilar development, leveraging reverse engineering expertise. The company has accumulated multiple international collaboration projects and expects its CDMO business to maintain growth momentum through 2027 and 2028.